Skip to main content

Albinterferon








Albinterferon


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search













Albinterferon
Clinical data
ATC code

  • L03AB12 (WHO) (albinterferon alfa-2b)

Identifiers
CAS Number
  • 472960-22-8

ChemSpider
  • none

Chemical and physical data
Formula
C3796H5937N1015O1143S50
Molar mass
85.7 kg/mol

Albinterferon (alb-IFN, trade name Albuferon) is a recombinant fusion protein drug consisting of interferon alpha (IFN-α) linked to human albumin.[1][2] Conjugation to human albumin prolongs the half-life of the IFN-α to about 6 days, allowing to dose it every two to four weeks.[3]


The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they will cease development of the drug.[4]


A French expert in hepatitis treatment, Dr. Yves Benhamou, member of the steering committee for a clinical trial of the drug was detained on criminal fraud charges by the F.B.I. agents on 11-01-2010 as he attended a conference in Boston because he allegedly tipped off a hedge fund manager about setbacks in the clinical trials (two participants in the trial had developed lung disease and one of them died); he had a consulting relationship with a manager of the hedge fund. The manager sold his entire stake in Human Genome Sciences before it announced the setbacks in Jan. 2008 and avoided $30 million in losses.[5][6]



References[edit]




  1. ^ Osborn BL, Olsen HS, Nardelli B, et al. (November 2002). "Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys". J. Pharmacol. Exp. Ther. 303 (2): 540–8. doi:10.1124/jpet.102.037002. PMID 12388634..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em


  2. ^ Statement on a nonproprietary name adopted by the USAN Council


  3. ^ Zeuzem S, Yoshida EM, Benhamou Y, et al. (August 2008). "Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C". Hepatology. 48 (2): 407–17. doi:10.1002/hep.22403. PMID 18666223.


  4. ^ https://www.google.com/hostednews/ap/article/ALeqM5h_xwTjacvhKutLYGE0w6FEuuaEQwD9ILM7MG1?docId=D9ILM7MG1


  5. ^ Kaplan, Thomas (November 2, 2010). "French Doctor Arrested on Insider Trading Charges". The New York Times.


  6. ^ http://newyork.fbi.gov/dojpressrel/pressrel10/nyfo110210a.htm












Retrieved from "https://en.wikipedia.org/w/index.php?title=Albinterferon&oldid=748835193"





Navigation menu

























(window.RLQ=window.RLQ||).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.536","walltime":"0.641","ppvisitednodes":"value":3945,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":175885,"limit":2097152,"templateargumentsize":"value":1380,"limit":2097152,"expansiondepth":"value":14,"limit":40,"expensivefunctioncount":"value":2,"limit":500,"unstrip-depth":"value":1,"limit":20,"unstrip-size":"value":10444,"limit":5000000,"entityaccesscount":"value":2,"limit":400,"timingprofile":["100.00% 499.055 1 -total"," 59.65% 297.694 1 Template:Drugbox"," 36.84% 183.861 1 Template:Infobox"," 22.83% 113.947 15 Template:Navbox"," 22.56% 112.592 1 Template:Reflist"," 18.41% 91.878 2 Template:Cite_journal"," 11.27% 56.248 16 Template:Unbulleted_list"," 6.82% 34.014 1 Template:Infobox_drug/chemical_formula"," 5.70% 28.439 1 Template:Interferons"," 5.21% 26.015 1 Template:Cytokine_receptor_modulators"],"scribunto":"limitreport-timeusage":"value":"0.212","limit":"10.000","limitreport-memusage":"value":4490713,"limit":52428800,"cachereport":"origin":"mw1238","timestamp":"20181010195520","ttl":1900800,"transientcontent":false);mw.config.set("wgBackendResponseTime":83,"wgHostname":"mw1263"););

Popular posts from this blog

The Dalles, Oregon

眉山市

清晰法令